-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ASCO 2021: Summary Overview and Outlook 2
ASCO 2021: Summary Overview and Outlook 2Roche Art Zhu monoclonal antibody (Tecentriq) is expected to become the first to be approved for perioperative treatment of non-small cell lung cancer immunity data Impower-010 in the study therapy, the study was just released Virtual Asco meeting on aid research Derived from.
Roche Art Zhu monoclonal antibody (Tecentriq) is expected to become the first to be approved for perioperative treatment of non-small cell lung cancer immunity data Impower-010 in the study therapy, the study was just released Virtual Asco meeting on aid research Derived from.
Roche’s atezolizumab, trade name Tecentriq, also known as T drug, is the first PD-L1 inhibitor approved for marketing ( approved by the FDA on May 18, 2016 for metastatic/recurrent urothelial cancer ).
FDA breast cancer
However, the fact that Impower-010's data shows that the disease-free survival (DFS) advantage seen in all populations is clearly driven by patients expressing PD-L1 will inhibit this victory.
The fact that Impower-010's data shows that the disease-free survival (DFS) advantage seen in all populations is clearly driven by patients expressing PD-L1 will inhibit this victory.
In addition to the patient's PD-L1 positive question, there are other subtle differences in the results.
NSCLC
Dr.
Moreover, among PD-L1 expressors, Tecentriq's two-year DFS rate was 74.
The median value has not yet been reached, but the use of Tecentriq can reduce the overall risk of disease recurrence by 34%, with a p value of 0.
However, the use of Tecentriq can reduce the overall risk of disease recurrence by 34%, with a p-value of 0.
Tecentriq also showed a 21% benefit Tecentriq also showed a 21% benefit
Dr.
diagnosis
The next analysis in the Impower-010 hierarchy will look at the DFS of all patients, including IB patients, and then the overall survival rate of all patients.
Even assisting a small part of the NSCLC market will enable Tecentriq to gain an important lead in the anti-PD-(L)1 competition.
Even assisting a small part of the NSCLC market will enable Tecentriq to gain an important lead in the anti-PD-(L)1 competition.
At least in Impower-010, this score is beyond doubt.
At least in Impower-010, this score is beyond doubt.
At least in Impower-010, this score is beyond doubt.
Leave a message here
